Author:
Bachmann Stephan,Iding Hans,Lautz Christian,Thomé-Pfeiffer Isabelle,Maierhofer Caroline,Mondière Régis,Schmidt Philipp,Strasser Christoph,Bär Thomas,Aebi André,Schuster Andreas
Abstract
Ipatasertib is a potent small molecule Akt kinase inhibitor currently tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the commercial manufacturing process is given. The convergent synthesis consists of ten steps with eight isolated intermediates and utilizes a wide range of chemical techniques and technologies to build-up this complex drug. All three stereocenters are introduced using enzyme or metal catalysis.
Subject
General Medicine,General Chemistry
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献